Biogen to Discontinue Clinical Development of Potential Treatment for Alzheimer's

   By Stephen Nakrosis 
 

Biogen Inc. said Wednesday it would discontinue clinical development of gosuranemab, which was being investigated as a potential treatment for Alzheimer's disease.

The company said its decision was based on results of its Phase 2 TANGO study of gosuranemab, an investigational anti-tau antibody. Biogen said the treatment didn't meet its primary efficacy endpoint "of change from baseline at week 78 on the Clinical Dementia Rating Scale-Sum of Boxes compared to placebo in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia." The company also said the treatment was well tolerated and safety outcomes were consistent with earlier studies.

Alfred Sandrock, head of Research and Development at Biogen, said, "While we are disappointed by the results of the Phase 2 study of gosuranemab, we know that the path to innovation is not a straight line, and that we always learn from each trial." He also said, "We are investing in a broad neuroscience pipeline, including other tau approaches for Alzheimer's disease."

--Write to Stephen Nakrosis at [e-mail]

(END) Dow Jones Newswires

June 16, 2021 17:16 ET (21:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.